GlobeNewswire Inc. · Aug 14, 2023
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company
AM
NASDAQ · AMTI
Applied Molecular Transport Inc.
Healthcare · Biotechnology
$0.26
Down-$0.01 (-3.13%)
Updated Sep 17, 2026, 5:07 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.01M
- P/E ratio
- -0.08
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 235.21K
- Avg. volume
- 316.86K
Price performance
AMTI price history
1M range · 0 trading sessions · Daily adjusted prices
AMTI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest AMTI news
The latest Smart Investors Daily articles mentioning AMTI.
Stock researchCompany · Overview
AMTI research
Overview
Company profile and research snapshot.
Company profile
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $1.70
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 28, 2023 | Chardan Capital | Neutral | — |
| Mar 6, 2023 | Chardan Capital | Buy | — |
| Feb 8, 2023 | Jefferies | Underperform | — |
| Jan 5, 2023 | B of A Securities | Underperform | — |
| Dec 27, 2022 | SVB Leerink | Market Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 28, 2023
3 Analysts Have This to Say About Applied Molecular
Over the past 3 months, 3 analysts have published their opinion on Applied Molecular (NASDAQ:AMTI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 0 2 0 Last 30D 0 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 1 0 3M Ago 0 0 0 1 0 These 3 analysts have an average price target of $1.3 versus the current price of Applied Molecular at $0.353, implying upside. Below is a summary of how these 3 analysts rated Applied Molecular over the past 3 months. The greater the number of ...Full story available on Benzinga.com
GlobeNewswire Inc. · Mar 27, 2023
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood, Ph.D., will leave his post as chief executive officer, but will remain as a board member. Shawn Cross, president and chief operating officer, will now serve as chief executive officer and has been appointed to the board where he will serve as chair.
Zacks Investment Research · Mar 14, 2023
What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock
Applied Molecular Transport Inc. (AMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
